Shire receives FDA approval for Vyvanse additional dosage strengths

Shire expects the three additional dosage strengths of 20mg, 40mg and 60mg will be available in retail pharmacies in the second quarter of 2008 to supplement the existing 30mg, 50mg and 70mg dosage strengths currently available in pharmacies.

Matt Emmens, CEO of Shire Pharmaceuticals, said: “Shire is pleased that physicians will soon have the benefit of a wider range of Vyvanse dosage strengths which they can prescribe to help manage the attention deficit hyperactivity disorder symptoms of their patients. In its first six months of availability, more than 500,000 Vyvanse prescriptions have been dispensed, indicating that physicians see Vyvanse as an effective treatment option for their patients.”